The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Efficacy and Safety of Pioglitazone Versus Metformin in Patients with Type 2 Diabetes Mellitus: A Double-Blind, Randomized Trial
Abstract
Pioglitazone increases the insulin sensitivity of peripheral tissues and may provide an alternative first-line treatment for type 2 diabetes. This study compared metabolic control in drug-naive type 2 diabetes patients given either pioglitazone or metformin. Eleven hundred and ninety-nine patients with poorly controlled type 2 diabetes mellitus [glycosylated hemoglobin (HbA1c), 7.5-11%; normal, 4.3-6.1%] were randomized to receive either pioglitazone (< or =45 mg/d) or metformin (< or =850 mg, three times daily). HbA1c, fasting plasma glucose (FPG), insulin levels, total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low density lipoprotein cholesterol, triglycerides, free fatty acids, and urinary albumin/creatinine ratio were measured. Mean HbA1c decreased in both treatment groups from baseline to wk 52 (-1.4% and -1.5%). Significantly greater mean reductions in FPG were observed in the pioglitazone group (-45.0 mg/dl; -2.5 mmol/liter) than in the metformin (-39.6 mg/dl; -2.2 mmol/liter) group (P = 0.016). Favorable changes in triglycerides and HDL-C were more pronounced with pioglitazone. Although low density lipoprotein cholesterol and TC levels increased with pioglitazone, TC/HDL-C ratios decreased similarly with both treatments. The urinary albumin/creatinine ratio was reduced by 19% with pioglitazone treatment, but remained unchanged with metformin therapy (-1%; P = 0.002). There was an increase in body weight of 1.9 kg in the pioglitazone group and a decrease of 2.5 kg in the metformin group. The overall frequency of adverse events was similar between treatment groups, but adverse event profiles were different between treatment groups. HbA1c reduction is similar after pioglitazone and metformin monotherapies, but differences in FPG, plasma lipids, and adverse effects between the two compounds may influence decision-making in individual prescribers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Friedewald, W. T., Levy, R. I., & Fredrickson, D. S. (1972) · Clinical Chemistry · doi:10.1093/clinchem/18.6.499 · Cited by 32,423
Turner, R. C., Fox, C., Matthews, McElroy, H. H., Cull, C. A., Holman, R. R., Neil, P., Hadden, D. R., Wright, D., Manley, E., et al. (1998) · The Lancet · Cited by 8,419
Role of AMP-Activated Protein Kinase in Mechanism of Metformin Action
Zhou, G., Myers, R., Li, Y., Chen, Y., Shen, X., Fenyk-Melody, J., Wu, M., Ventre, J., Doebber, T., Fujii, N., et al. (2001) · Journal of Clinical Investigation · doi:10.1172/jci13505 · Cited by 5,652 · cited 1×
“The metabolic effects of metformin may be due to its ability to phosphorylate and activate AMP-activated protein kinase (8).”
BackgroundLow-Density Lipoprotein Subclass Patterns and Risk of Myocardial Infarction
Austin, M. A. (1988) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1988.03410130125037 · Cited by 1,780
Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus
DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Haffner, S. M., Greenberg, A. S., Weston, W. M., Chen, H., Williams, K., & Freed, M. I. (2002) · Circulation · doi:10.1161/01.cir.0000025403.20953.23 · Cited by 884
Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
Steinberg, H. O., Tarshoby, M., Monestel, R., Hook, G., Cronin, J., Johnson, A., Bayazeed, B., & Baron, A. D. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119636 · Cited by 761
Pagano, G., Pacini, G., Musso, G., Gambino, R., Mecca, F., Depetris, N., Cassader, M., David, E., Cavallo-Perin, P., & Rizzetto, M. (2002) · Hepatology · doi:10.1053/jhep.2002.30690 · Cited by 753
Miyazaki, Y., Mahankali, A., Matsuda, M., Mahankali, S., Hardies, J., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.87.6.8567 · Cited by 726
Stehouwer, C. D. A., Gall, M.-A., Twisk, J. W. R., Knudsen, E., Emeis, J. J., & Parving, H.-H. (2002) · Diabetes · doi:10.2337/diabetes.51.4.1157 · Cited by 652
Aronoff, S., Rosenblatt, S., Braithwaite, S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 629
Fatty acids, lipotoxicity and insulin secretion
McGarry, J. D., & Dobbins, R. L. (1999) · Diabetologia · doi:10.1007/s001250051130 · Cited by 552
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519
Sheth, S. G., Gordon, F. D., & Chopra, S. (1997) · Annals of Internal Medicine · doi:10.7326/0003-4819-126-2-199701150-00008 · Cited by 513
Assmann, G., & Schulte, H. (1988) · American Heart Journal · doi:10.1016/0002-8703(88)90220-7 · Cited by 449
Pathophysiology and Pharmacological Treatment of Insulin Resistance*
Matthaei, S., Stumvoll, M., Kellerer, M., & Häring, H.-U. (2000) · Endocrine Reviews · doi:10.1210/edrv.21.6.0413 · Cited by 377
Einhorn, D., Rendell, M., Rosenzweig, J., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2000) · Clinical Therapeutics · doi:10.1016/s0149-2918(00)83039-8 · Cited by 368
Kipnes, M. S., Krosnick, A., Rendell, M. S., Egan, J. W., Mathisen, A. L., & Schneider, R. L. (2001) · The American Journal of Medicine · doi:10.1016/s0002-9343(01)00713-6 · Cited by 281
Free Fatty Acid as a Link in the Regulation of Hepatic Glucose Output by Peripheral Insulin
Rebrin, K., Steil, G. M., Getty, L., & Bergman, R. N. (1995) · Diabetes · doi:10.2337/diab.44.9.1038 · Cited by 270
Glitazones: clinical effects and molecular mechanisms
Stümvoll, M., & Häring, H. (2002) · Annals of Medicine · doi:10.1080/713782132 · Cited by 225
Effect of Troglitazene on Microalbuminuria in Patients With Incipient Diabetic Nephropathy
Imano, E., Kanda, T., Nakatani, Y., Nishida, T., Arai, K., Motomura, M., Kajimoto, Y., Yamasaki, Y., & Hori, M. (1998) · Diabetes Care · doi:10.2337/diacare.21.12.2135 · Cited by 196
Grundy, S. M., & Vega, G. L. (1992) · Archives of Internal Medicine · doi:10.1001/archinte.152.1.28 · Cited by 145
Proinsulin Is an Independent Predictor of Coronary Heart Disease
Zethelius, B., Byberg, L., Hales, C. N., Lithell, H., & Berne, C. (2002) · Circulation · doi:10.1161/01.cir.0000015855.04844.e7 · Cited by 121
Worldwide Experience of Metformin as an Effective Glucose-lowering Agent: A Meta-analysis
Campbell, I. W., & Howlett, H. C. S. (1995) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610110509 · Cited by 121
Hematocrit and the risk of coronary heart disease mortality
Brown, D. W., Giles, W. H., & Croft, J. B. (2001) · American Heart Journal · doi:10.1067/mhj.2001.118467 · Cited by 100
Effect of metformin on peripheral insulin sensitivity in non insulin dependent diabetes mellitus.
Prager, R., Schernthaner, G.-H., & Graf, H. (1986) · PubMed · Cited by 96
Self-citationThiazolidinediones and type 2 diabetes: new drugs for an old disease
O'Moore‐Sullivan, T. M., & Prins, J. B. (2002) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2002.tb04461.x · Cited by 76
Nakamura, T., Ushiyama, C., Suzuki, S., Shimada, N., Sekizuka, K., Ebihara, L., & Koide, H. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00463.x · Cited by 61
Prager, R., & Schernthaner, G. (1983) · Diabetes · doi:10.2337/diab.32.12.1083 · Cited by 58
Self-citationOverweight: Fat Distribution and Health Risks. Epidemiological Observations
Seidell, J. C., HAUTVAST, J. G. A. J., & Deurenberg, P. (1989) · Transfusion Medicine and Hemotherapy · doi:10.1159/000222401 · Cited by 43
Winkler, K., Friedrich, I., Baumstark, M. W., Wieland, H., & März, W. (2002) · The British Journal of Diabetes · doi:10.1177/14746514020020021301 · Cited by 25
New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
Brown, D. L., & Brillon, D. J. (1999) · PubMed · Cited by 14
Weir, G. C. (1995) · JAMA · doi:10.1001/jama.1995.03520470086039 · Cited by 13
Cited by
Authors/Task Force Members, Ryden, L., Standl, E., Bartnik, M., Van den Berghe, G., Betteridge, J., de Boer, M.-J., Cosentino, F., Jonsson, B., Laakso, M., et al. (2006) · European Heart Journal · doi:10.1093/eurheartj/ehl260 · Cited by 1,647
Self-citationRisk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub4 · Cited by 893
Fleseriu, M., Biller, B. M. K., Findling, J. W., Molitch, M. E., Schteingart, D. E., Gross, C., on behalf of the SEISMIC Study Investigators, The SEISMIC Study Investigators include, Auchus, R., Bailey, T., et al. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-3350 · Cited by 479
Gandini, S., Puntoni, M., Heckman-Stoddard, B. M., Dunn, B. K., Ford, L., DeCensi, A., & Szabo, E. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-13-0424 · Cited by 457
Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus
Salpeter, S. R., Greyber, E., Pasternak, G. A., & Salpeter (posthumous), E. E. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002967.pub3 · Cited by 434
Metadata
- Authors
- Schernthaner, G., Matthews, D. R., Charbonnel, B., Hanefeld, M., & Brunetti, P.
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2004-12
- Volume
- 89
- Issue
- 12
- Pages
- 6068-6076
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2121776978
- Cited by
- 268
- References
- 35
- FWCI
- 14.88
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.